Overview


The Chronic Kidney Disease Diagnostics Market involves technologies and tests like blood, urine, imaging, and biomarker assays used for early detection and monitoring of CKD, driven by rising disease prevalence, AI-enabled innovations, and growth in telemedicine and point-of-care testing.

According to FutureWise analysis, the chronic kidney disease diagnostics market in 2026 is US$1.39 billion and is expected to reach US$2.47 billion by 2036 at a CAGR of 5.92%. The global rise in diabetes and hypertension, major risk factors for chronic kidney disease (CKD), is increasing the demand for early diagnostic solutions. Innovations in biomarker tests and point-of-care diagnostics are enhancing the early detection and monitoring of kidney function.

Growth Drivers:

  • Rising prevalence of chronic kidney disease (CKD) worldwide.
  • Increasing adoption of advanced diagnostic technologies, including AI and biomarker-based assays.
  • Growing awareness of early detection and preventive healthcare.
  • Expansion of point-of-care and home-based testing solutions.
  • Integration of digital health and telemedicine for remote monitoring.

Key Trends:

  • Growing adoption of AI and machine learning in diagnostic platforms for early detection and predictive accuracy.
  • Increasing use of novel biomarkers and multi-omics approaches for more sensitive and earlier CKD detection.
  • Expansion of point-of-care and remote monitoring solutions, including home-based and smartphone-linked tests.
  • Integration of digital health platforms and telemedicine to support continuous CKD monitoring and patient engagement.

Market Segmentation and Key Players:

The Chronic Kidney Disease Diagnostics Market is segmented by product type—including blood tests, urine tests, imaging tests, and other diagnostic methods—by end-user into hospitals, clinics, and diagnostic laboratories, and by region, covering major markets in North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. Comprehensive segmentation details are provided in the Segmentation section below.

Major companies operating in the Chronic Kidney Disease Diagnostics Market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers, AbbVie Inc., and Sysmex Corporation, which are advancing diagnostic solutions and expanding their global reach.

Research Methodology:

The Chronic Kidney Disease Diagnostics Market research by FutureWise Research combines primary interviews with industry experts and secondary data from reports, publications, and databases. Market size and forecasts are estimated using top-down and bottom-up approaches, validated through triangulation, while segmentation by product type, end-user, and region highlights key trends, growth drivers, and competitive dynamics.

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Beckman Coulter
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Pfizer Inc
  • Siemens Healthineers
  • Sysmex Corporation
  • Teva Pharmaceutical Industries Ltd

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in  Chronic Kidney Disease Diagnostics Market:

Abbott Laboratories

Abbott’s Afinion™ ACR assay, used on the Afinion 2 System, provides a quantitative analysis of urinary albumin, creatinine, and the albumin-to-creatinine ratio (uACR) in about 5 minutes, enabling swift identification of early-stage chronic kidney disease (CKD) in patients at high risk, such as those with diabetes or hypertension.

Pfizer Inc

Pacibekitug, a monoclonal antibody targeting IL-6 that was initially licensed from Pfizer, has recently finished its Phase II "TRANQUILITY" trial in patients with chronic kidney disease (CKD) exhibiting increased inflammation. It effectively lowered high-sensitivity CRP levels, making it a potential anti-inflammatory strategy for managing CKD.

By Product Type

  • By Diagnosis
    • Blood Tests
    • Urine Tests
    • Imaging Tests
    • Others
  • By Treatment
    • Drug Class
      • ACE Inhibitors
      • Angiotensin-II Receptor Blockers
      • Diuretics
      • Other
    • Dialysis
    • Other

By End-User

  • Hospitals
  • Clinics
  • Diagnostic labs

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Here’s a regional view of where the most progress is happening:

The Asia-Pacific (APAC) region is witnessing substantial growth in the Chronic Kidney Disease (CKD) diagnostics market. This expansion is driven by several factors, including a large and aging population, a rising prevalence of risk factors such as diabetes and hypertension, and improvements in healthcare infrastructure.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the global Chronic Kidney Disease Diagnostics Market On The Basis Of Product Type, End User, and Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and Middle East and Africa
  • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Chronic Kidney Disease Diagnostics Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Chronic Kidney Disease Diagnostics Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Chronic Kidney Disease Diagnostics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Chronic Kidney Disease Diagnostics Market, By Product Type Historical Analysis and Forecast 2026-2036 (USD Million)

    •   1. By Diagnosis
         1.1. Blood Tests
         1.2. Urine Tests
         1.3. Imaging Tests
         1.4. Others
        2. By Treatment
         2.1. Drug Class
          2.1.1. ACE Inhibitors
          2.1.2. Angiotensin-II Receptor Blockers
          2.1.3. Diuretics
          2.1.4. Other
         2.2. Dialysis
         2.3. Other

  • 8.   Chronic Kidney Disease Diagnostics Market, By End-User Historical Analysis and Forecast 2026-2036 (USD Million)

    •   1. Hospitals
        2. Clinics
        3. Diagnostic labs

  • 9.   North America Chronic Kidney Disease Diagnostics Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2026-2036

  • 10.   Latin America Chronic Kidney Disease Diagnostics Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2026-2036

  • 11.   Europe Chronic Kidney Disease Diagnostics Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2026-2036

  • 12.   Asia Pacific Chronic Kidney Disease Diagnostics Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2026-2036

  • 13.   Middle East and Africa Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2026-2036

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Abbott Laboratories
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. AbbVie Inc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Amgen Inc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Beckman Coulter
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. F. Hoffmann-La Roche Ltd
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. GlaxoSmithKline Plc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Pfizer, Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Siemens Healthineers
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Sysmex Corporation
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Teva Pharmaceutical Industries Ltd.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.   FutureWise SME Key Takeaway Points for Client

FAQ


These solutions enable rapid, decentralized testing, providing real-time monitoring and facilitating early intervention. They also reduce hospital dependency and improve patient compliance through user-friendly, smartphone-compatible devices.

Innovations encompass new biomarkers, multi-omics testing, AI-enhanced predictive analytics, and sophisticated imaging technologies that facilitate earlier detection and tailored treatment planning.

Chronic Kidney Disease (CKD) is a progressive condition in which the kidneys gradually lose their ability to effectively filter waste and excess fluids from the blood, often resulting in kidney failure if not treated.

Data accuracy relies on standardized laboratory procedures, validated biomarker assays, quality-controlled imaging protocols, and AI-based algorithms that cross-check multiple parameters for reliable staging and monitoring.

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 113 519 7222
  • US : +1 347 709 4931

Related Market

Late Stage Chronic Kidney Disease Therapeutics Market

Read More

Diabetic Kidney Disease Market

Read More

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11